Cancer drug repurposing in autism spectrum disorder

Area of Science:

• Neuroscience
• Oncology
• Pharmacology

Background:

• Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with limited understanding of its mechanisms and a lack of effective treatments.
• Genetic diversity in ASD complicates traditional drug development, necessitating novel therapeutic strategies.
• The rising incidence of ASD diagnoses underscores the critical need for innovative interventions.

Purpose of the Study:

• To explore shared molecular pathways between ASD and cancer.
• To highlight the potential of repurposing established cancer drugs for ASD treatment.
• To discuss key considerations for successful drug repurposing in ASD.

Main Methods:

• Review of scientific literature focusing on molecular pathways common to ASD and cancer.
• Identification of existing cancer drugs with potential therapeutic applications in ASD.
• Analysis of factors influencing the efficacy and safety of repurposed drugs.

Main Results:

• Shared molecular pathways, including mTOR signaling, histone deacetylase activity, and inflammatory processes, are implicated in both ASD and cancer.
• Specific classes of cancer drugs, such as mTOR inhibitors, histone deacetylase inhibitors, and anti-inflammatory agents, show promise for ASD treatment.
• Optimizing trial design, considering drug dosage, patient age, side effects, and commercial viability are crucial for successful repurposing.

Conclusions:

• Repurposing cancer drugs represents a promising avenue for developing novel ASD therapies.
• Targeting shared molecular pathways offers a rational approach to drug development for ASD.
• Addressing practical challenges in clinical trials and drug development pipelines is essential for translating this potential into effective treatments.